Antonia Vlahou, PhD
Staff Research Scientist A'

Telephone : +30 210 6597 506
Fax : +30 210 6597 545
e-mail : vlahoua@bioacademy.gr

Center :

Systems Biology

Lab Site :

Vlahou Lab

Core Facility Site :

Proteomics

Brief Bio

Dr.  Antonia Vlahou received her BS from the School of Biology, University of Athens, Greece and her Ph.D from the Department of Cell Biology, Baylor College of Medicine, Houston Texas. Dr. Vlahou pursued post-doctoral studies at the Eastern VA Medical School, VA, where she was appointed as a Research Assistant Professor from 2001 until 2003 when she moved to the Biomedical Research Foundation of the Academy of Athens (BRFAA). Dr. Vlahou is currently the co-Director of the Proteomics Research Unit at the BRFAA. During her doctoral and post-doctoral studies Dr. Vlahou received various awards including an award for best oral presentation, Southwestern Developmental Biology Conference, the AFUD/AUA fellowship (1998-2000) as well as the Pfizer Scholar in Urology award (2000). Dr. Vlahou is a highly experienced researcher in the field of clinical proteomics. She has been the Coordinator of the European COST Action on Kidney and Urine Proteomics (EuroKUP) (2008 -2012) as well as the Coordinator of the Marie Curie ITN program (“Clinical and system –omics for the identification of the Molecular DEterminants of established Chronic Kidney Disease”, iMODE-CKD) και EU FP7 “Translation of novel Biomarkers for Bladder Cancer for clinical outcome prediction” (TransBioBC) projects. Since 2010 she serves as external expert for biomarker qualification at the European Medicines Agency (EMA, UK). She has served as group leader in various EU or natonal funded projects (NeuriNox, SysVasc, Marie Curie EID BCMolMed, Transpot, Caresyan, mELISA, myBioTag). Since 2014 she has been Board Member of theEuropean Society of Urological Research (ESUR) -European Association of Urology (EAU).

Selected Publications

Vlahou A, Hallinan D, Apweiler R, Argiles A, Beige J, Benigni A, Bischoff R, Black PC, Boehm F, Céraline J, Chrousos GP, Delles C, Evenepoel P, Fridolin I, Glorieux G, van Gool AJ, Heidegger I, Ioannidis JPA, Jankowski J, Jankowski V, Jeronimo C, Kamat AM, Masereeuw R, Mayer G, Mischak H, Ortiz A, Remuzzi G, Rossing P, Schanstra JP, Schmitz-Dräger BJ, Spasovski G, Staessen JA, Stamatialis D, Stenvinkel P, Wanner C, Williams SB, Zannad F, Zoccali C, Vanholder R. Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics? (2021) Hypertension, 77(4):1029-1035. doi: 10.1161/HYPERTENSIONAHA.120.16340. Epub 2021 Feb 15.

He T, Melgarejo JD, Clark AL, Yu YL, Thijs L, Díez J, López B, González A, Cleland JG, Schanstra JP, Vlahou A, Latosinska A, Mischak H, Staessen JA, Zhang ZY, Jankowski V. Serum and urinary biomarkers of collagen type-I turnover predict prognosis in patients with heart failure. (2021) Clin Transl Med., 11(1):e267. doi: 10.1002/ctm2.267.

Nikolaou PE, Efentakis P, Abu Qourah F, Femminò S, Makridakis M, Kanaki Z, Varela A, Tsoumani M, Davos CH, Dimitriou CA, Tasouli A, Dimitriadis G, Kostomitsopoulos N, Zuurbier CJ, Vlahou A, Klinakis A, Brizzi MF, Iliodromitis EK, Andreadou I. Chronic Empagliflozin Treatment Reduces Myocardial Infarct Size in Nondiabetic Mice Through STAT-3-Mediated Protection on Microvascular Endothelial Cells and Reduction of Oxidative Stress. (2021) Antioxid Redox Signal., 34(7):551-571. doi: 10.1089/ars.2019.7923.

Frantzi M, Latosinska A, Mokou M, Mischak H, Vlahou A. Drug repurposing in oncology.
(2020) Lancet Oncol., 21(12):e543. doi: 10.1016/S1470-2045(20)30610-0.

Mokou M, Lygirou V, Angelioudaki I, Paschalidis N, Stroggilos R, Frantzi M, Latosinska A, Bamias A, Hoffmann MJ, Mischak H, Vlahou A. A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients' Omics Signatures. (2020) Cancers (Basel), 26;12(12):3519. doi: 10.3390/cancers12123519.

Makridakis, M., Kontostathi, G., Petra, E., Stroggilos, R., Lygirou, V., Filip, S., Duranton, F., Mischak, H., Argiles, A., Zoidakis, J., Vlahou, A. Multiplexed MRM-based protein quantification of putative prognostic biomarkers for chronic kidney disease progression in plasma (2020) Scientific Reports, 10 (1), art. no. 4815, DOI: 10.1038/s41598-020-61496-z

Mantsiou, A., Makridakis, M., Fasoulakis, K., Katafigiotis, I., Constantinides, C.A., Zoidakis, J., Roubelakis, M.G., Vlahou, A., Lygirou, V. Proteomics Analysis of Formalin Fixed Paraffin Embedded Tissues in the Investigation of Prostate Cancer (2020) Journal of Proteome Research, 19 (7), pp. 2631-2642. DOI: 10.1021/acs.jproteome.9b00587

Stroggilos, R., Mokou, M., Latosinska, A., Makridakis, M., Lygirou, V., Mavrogeorgis, E., Drekolias, D., Frantzi, M., Mullen, W., Fragkoulis, C., Stasinopoulos, K., Papadopoulos, G., Stathouros, G., Lazaris, A.C., Makrythanasis, P., Ntoumas, K., Mischak, H., Zoidakis, J., Vlahou, A. Proteome-based classification of Nonmuscle Invasive Bladder Cancer (2020) International Journal of Cancer, 146 (1), pp. 281-294. DOI: 10.1002/ijc.32556

Chasapis, C.T., Makridakis, M., Damdimopoulos, A.E., Zoidakis, J., Lygirou, V., Mavroidis, M., Vlahou, A., Miranda-Vizuete, A., Spyrou, G., Vlamis-Gardikas, A. Implications of the mitochondrial interactome of mammalian thioredoxin 2 for normal cellular function and disease (2019) Free Radical Biology and Medicine, 137, pp. 59-73.  DOI: 10.1016/j.freeradbiomed.2019.04.018

Mokou, M., Klein, J., Makridakis, M., Bitsika, V., Bascands, J.-L., Saulnier-Blache, J.S., Mullen, W., Sacherer, M., Zoidakis, J., Pieske, B., Mischak, H., Roubelakis, M.G., Schanstra, J.P., Vlahou, A. Proteomics based identification of KDM5 histone demethylases associated with cardiovascular disease(2019) EBioMedicine, 41, pp. 91-104. DOI: 10.1016/j.ebiom.2019.02.040

Schanstra, J.P., Luong, T.T.D., Makridakis, M., Van Linthout, S., Lygirou, V., Latosisnska, A., Alesutan, I., Boehme, B., Schelski, N., Von Lewinski, D., Mullen, W., Nicklin, S., Delles, C., Feuillet, G., Denis, C., Lang, F., Pieske, B., Bascands, J.-L., Mischak, H., Saulnier-Blache, J.-S., Voelkl, J., Vlahou, A*., Klein, J. Systems biology identifies cytosolic PLA2 as a target in vascular calcification treatment (2019) JCI Insight, 4 (10), art. no. e125638 DOI: 10.1172/jci.insight.125638 (*equal contributing last author)

Luong, T.T.D., Schelski, N., Boehme, B., Makridakis, M., Vlahou, A., Lang, F., Pieske, B., Alesutan, I., Voelkl, J. Fibulin-3 Attenuates Phosphate-Induced Vascular Smooth Muscle Cell Calcification by Inhibition of Oxidative Stress (2018) Cellular Physiology and Biochemistry, 46 (4), pp. 1305-1316.  DOI: 10.1159/000489144

PubMed: